Medication info
Sitapholmin XR Sustained Release Tablet 50/1000 mg

Sitapholmin XR Sustained Release Tablet 50/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletSitagliptin Phosphate Hydrate›64.25mg / 1 tablet
Manufacturer / importer
Jongkundang Co., Ltd.
Appearance
Light green, bilaterally convex, oval-shaped sustained release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201504897 · Approved 2015.07.16 · Insurance code 643307380

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dosage of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this drug should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this drug must be swallowed whole and should not be split, crushed, ground, or chewed. Cases have been reported in which the drug was incompletely dissolved and excreted in the feces. It is not known whether the material excreted in the feces contains the active ingredients of the drug. If a patient repeatedly reports finding this drug in their feces, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Take 1 tablet of this drug 100/1000 mg extended-release tablets once daily. Patients taking this drug 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets at the same time once daily. Patients not currently receiving metformin treatment: For patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Patients Who Must Not Take This Drug). Patients receiving metformin treatment: For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial total daily dose of this drug is sitagliptin 100 mg and the patient's current metformin dose. Patients switching from concomitant sitagliptin and metformin therapy to this drug may start at their current doses of sitagliptin and metformin. Patients taking immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with this drug 50/1000 mg extended-release tablets at a dose of 2 tablets once daily. When adequate blood glucose control cannot be achieved with concomitant metformin and sulfonylurea therapy, metformin and insulin therapy, or metformin and thiazolidinedione therapy: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this drug in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this drug, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Drug).

Ingredients

Manufacturer
Jongkundang Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • difficulty in blood sugar control
View approved original text

This medication is used to improve blood sugar control in adult patients with type 2 diabetes mellitus as an adjunct to diet and exercise. It is suitable for patients who have not previously received diabetes medication treatment or who have difficulty controlling blood sugar with monotherapy. Moreover, it is used in combination when sufficient efficacy is not obtained from monotherapy with metformin or sitagliptin. It is also effective when used together with other diabetes medications such as sulfonylureas, thiazolidinediones, or insulin when blood sugar control is difficult. In summary, this drug is used for the treatment of patients with type 2 diabetes who have difficulty controlling blood sugar with various single or combination therapies.

How to take

Adult dose

In antidiabetic therapy, the dosage of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this drug should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this drug must be swallowed whole and should not be split, crushed, ground, or chewed. Cases have been reported in which the drug was incompletely dissolved and excreted in the feces. It is not known whether the material excreted in the feces contains the active ingredients of the drug. If a patient repeatedly reports finding this drug in their feces, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Take 1 tablet of this drug 100/1000 mg extended-release tablets once daily. Patients taking this drug 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets at the same time once daily. Patients not currently receiving metformin treatment: For patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Patients Who Must Not Take This Drug). Patients receiving metformin treatment: For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial total daily dose of this drug is sitagliptin 100 mg and the patient's current metformin dose. Patients switching from concomitant sitagliptin and metformin therapy to this drug may start at their current doses of sitagliptin and metformin. Patients taking immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with this drug 50/1000 mg extended-release tablets at a dose of 2 tablets once daily. When adequate blood glucose control cannot be achieved with concomitant metformin and sulfonylurea therapy, metformin and insulin therapy, or metformin and thiazolidinedione therapy: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this drug in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this drug, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Drug).

Precautions

This medication contains sitagliptin and metformin, and is used in the treatment of diabetes. While taking this medication, serious allergic reactions may occur rarely. If you experience symptoms such as skin rashes, difficulty breathing, or swelling of the face or neck, discontinue use immediately and consult a doctor. Pancreatitis can cause inflammation of the pancreas; if symptoms such as severe abdominal pain, nausea, vomiting, or fever occur, visit a hospital immediately. This medication should not be administered to patients with impaired kidney function, dehydration, severe infections, or heart failure, and should be discontinued for a period before and after surgery. It is safe for pregnant or possibly pregnant women and nursing mothers not to take this medication. This medication may cause hypoglycemia, so it is advisable to eat regularly and avoid vigorous exercise or alcohol consumption. Elderly patients with impaired kidney function should be particularly cautious and should have regular kidney function tests. During treatment, Vitamin B12 levels may drop, so regular blood tests are necessary, and vitamin supplementation may be needed if symptoms arise. There may be interactions when taken with other medications, so if you are taking other medicines, be sure to inform your doctor or pharmacist. If unusual symptoms such as sudden weight gain, breathlessness, severe joint pain, or skin blisters appear while taking this medication, consult medical personnel immediately. In case of overdose, emergency treatment is required as this medication can be partially removed by hemodialysis. To enhance the therapeutic effect of this medication, it should be combined with dietary therapy and regular exercise, and regular monitoring of blood sugar levels and kidney function should be performed.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
  • nausea
Show 18 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • vesicular dermatitis
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rash
  • urticaria
  • cutaneous vasculitis
  • elevated liver enzymes
  • acute renal failure
  • severe hypoglycemia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. The recommended storage temperature is room temperature between 1 and 30 degrees Celsius. Storing it this way helps maintain its efficacy and safety for a longer period.

Appearance and packaging

Appearance

Light green, bilaterally convex, oval-shaped sustained release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.